ArticleAntimicrobial agents and chemotherapy2022
New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae.
Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 87 citations in OpenAlex.
- ISEmerging microbes & infections · 2026Article
- Cefiderocol resistance in a clinical ST11-KL64 hypervirulent Klebsiella pneumoniae isolate mediated by a novel CirA truncation and SHV-12 β-lactamase.BMC microbiology · 2026Article
- Vitamin B12 promotes cefiderocol resistance and small-colony variants in carbapenem-resistantmBio · 2026Article
- An integrated phenotypic and genomic approach to characterize MBL-producing Enterobacterales strains circulating in a Sicilian transplant center.Microbiology spectrum · 2026Article
- Small colony variants and cefiderocol resistance in clinicalFrontiers in microbiology · 2026Article
- Ferrichrome: bacterial function, synthetic mimics, and biomedical applications.Frontiers in microbiology · 2026Review
- Genetic and phenotypic characterization of the plasmid-encoded NDM-80 metallo-β-lactamase inFrontiers in microbiology · 2026Article
- High-risk clonal expansion of IMP-producingAntimicrobial agents and chemotherapy · 2025Article
- The Achilles' heel of the Trojan Horse? A systematic evaluation of cefiderocol susceptibility testing.The Journal of antimicrobial chemotherapy · 2025Article
- Evidence for early circulation of the M1UK sublineage of Streptococcus pyogenes in Germany, 2015-2023.Emerging microbes & infections · 2025Article
- Efficacy of cefiderocol in combination with xeruborbactam versus taniborbactam against cefiderocol-resistant NDM-producingAntimicrobial agents and chemotherapy · 2025Article
- Occurrence of KPC-71 or the presence of NDM combined with a high expression ofMicrobiology spectrum · 2025Article
- Combined resistance mechanisms leading to high-level of cefiderocol resistance among NDM-like producing E. coli ST167 clinical isolates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Emerging resistance to novel β-lactam β-lactamase inhibitor combinations in Klebsiella pneumoniae bearing KPC variants.Journal of global antimicrobial resistance · 2025Article
- Article
- Evaluating Antimicrobial Susceptibility Testing Methods for Cefiderocol: A Review and Expert Opinion on Current Practices and Future Directions.Antibiotics (Basel, Switzerland) · 2025Review
- Mechanisms of Cefiderocol Resistance in Carbapenemase-Producing Enterobacterales: Insights from Comparative Genomics.Antibiotics (Basel, Switzerland) · 2025Article
- Cefiderocol "under siege"? Understanding the rise of NDM-mediated resistance to novel agents.Chemical science · 2025Article
- High Prevalence of Cefiderocol Resistance Among New Delhi Metallo-β-Lactamase ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Global molecular epidemiology of the incomplete CirA protein related to cefiderocol resistance inMicrobiology spectrum · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cefiderocol is a promising novel siderophore cephalosporin for the treatment of multidrug-resistant Gram-negative bacilli and with stability against degradation by metallo-β-lactamases. Nonetheless, the emergence of cefiderocol in metallo-β-lactamase-producing Enterobacterales during therapy has been reported on more than one occasion. To understand the underlying mechanisms and factors facilitating the resistance development, we conducted an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.